Cellics Therapeutics
San Diego
About Cellics Therapeutics
Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines. It was created with the goal of applying Nanosponge Technology to treat and prevent diseases. It aims to employ innovative biomimetic nanomedicines to address serious diseases with a high unmet medical need. The company’s initial primary focus is on autoimmune and inflammatory diseases and difficult to treat infectious diseases. Additionally, Cellics is seeking to develop best-in-class vaccines for various diseases. The company is currently on schedule to advance its lead product candidate CTI-005 to human clinical trials for the treatment of bacterial pneumonia. It is the passion and goal of Cellics to use advanced technology to help human beings live healthier and longer lives. The company was founded in 2014 and is headquartered in San Diego, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $36.9M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2022)
- Website: cellics.com
- Phone: +1 858 412 6148
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cellics-therapeutics-57054 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.